Journal of Biological Chemistry · 2006 · 188 citations · 43 references
Life SciencesBiochemistryMolecular BiologyInnate ImmunitySignal TransductionStructural BiologyCell-surface ReceptorsExtracellular MatrixLigand BindingProtein DomainsProtein Interaction DomainsProtein-ligand BindingCleavageCleavage EfficiencyEndocytic Cargo ReceptorsGelatinase ActivityMatrix Metalloproteinase Gene FamilyMatrix Metalloproteinases
Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of ∼64 amino acid residues. This linker sequence is demonstrated to be an extensively O-glycosylated (OG) domain with a compact three-dimensional structure. The OG and hemopexin domains have no influence on the cleavage efficiency of MMP-9 substrates. In contrast, the hemopexin domain contains a binding site for the cargo receptor low density lipoprotein receptor-related protein-1 (LRP-1). Furthermore, megalin/LRP-2 is identified as a new functional receptor for the hemopexin domain of MMP-9, able to mediate the endocytosis and catabolism of the enzyme. The OG domain is required to correctly orient the hemopexin domain for inhibition by TIMP-1 and internalization by LRP-1 and megalin. Therefore, the OG and hemopexin domains down-regulate the bioavailability of active MMP-9 and the interactions with the cargo receptors are proposed to be the original function of hemopexin domains in MMPs. Gelatinase B/matrix metalloproteinase-9 (MMP-9), a key regulator and effector of immunity, contains a C-terminal hemopexin domain preceded by a unique linker sequence of ∼64 amino acid residues. This linker sequence is demonstrated to be an extensively O-glycosylated (OG) domain with a compact three-dimensional structure. The OG and hemopexin domains have no influence on the cleavage efficiency of MMP-9 substrates. In contrast, the hemopexin domain contains a binding site for the cargo receptor low density lipoprotein receptor-related protein-1 (LRP-1). Furthermore, megalin/LRP-2 is identified as a new functional receptor for the hemopexin domain of MMP-9, able to mediate the endocytosis and catabolism of the enzyme. The OG domain is required to correctly orient the hemopexin domain for inhibition by TIMP-1 and internalization by LRP-1 and megalin. Therefore, the OG and hemopexin domains down-regulate the bioavailability of active MMP-9 and the interactions with the cargo receptors are proposed to be the original function of hemopexin domains in MMPs. Matrix metalloproteinases (MMPs) 3The abbreviations used are: MMPs, matrix metalloproteinases; 2-AB, 2-aminobenzamide; fl, full-length; GU, glucose units; HPA, helix pomatia agglutinin; IL, interleukin; LC-ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry; LRP, low density lipoprotein receptor-related protein; MCP-3, monocyte chemotactic protein-3; mGCP-2/LIX, mouse granulocyte chemotactic protein-2; MT-, membrane type-; NGAL, neutrophil gelatinase B-associated lipocalin; OG, O-glycosylated; RU, response units; SPR, surface plasmon resonance; TIMP, tissue inhibitor of MMPs. constitute a family of Zn2+-dependent proteases, which share a number of conserved protein domains (1Nagase H. Woessner J.F. J. Biol. Chem. 1999; 274: 21491-21494Abstract Full Text Full Text PDF PubMed Scopus (3903) Google Scholar). All MMPs consist of a propeptide and a Zn2+-containing active site, and most MMPs have a C-terminal hemopexin domain. Some MMPs contain additional domains, e.g. in MT-MMPs, the hemopexin domain is connected to a membrane anchor, and in MMP-2 (gelatinase A) and MMP-9 (gelatinase B), a fibronectin domain is inserted in the active site. In MMP-9, a unique linker sequence of unknown function connects the active site and the hemopexin domain, and is more than 50 amino acids long (in contrast to ∼10 residues for the linker sequence in other MMPs). It has been considered to be an independent protein domain and has low homology with collagen type V (2Wilhelm S.M. Collier I.E. Marmer B.L. Eisen A.Z. Grant G.A. Goldberg G.I. J. Biol. Chem. 1989; 264: 17213-17221Abstract Full Text PDF PubMed Google Scholar), mainly because of its high proline content. Because we show in the present study that it contains O-linked glycans, it is henceforth named the O-glycosylated (OG) domain. MMP-9 degrades extracellular matrix components and cleaves a variety of soluble proteins, including cytokines and chemokines. Overexpression of MMP-9 leads to inflammation, tissue destruction, and pathology (3Opdenakker G. Van den Steen P.E. Van Damme J. Trends Immunol. 2001; 22: 571-579Abstract Full Text Full Text PDF PubMed Scopus (351) Google Scholar, 4Parks W.C. Wilson C.L. Lopez-Boado Y.S. Nat. Rev. Immunol. 2004; 4: 617-629Crossref PubMed Scopus (1481) Google Scholar). Therefore, expression of MMP-9 is highly regulated at the levels of transcription, translation, and secretion. Once secreted, the activity is tightly kept in check by proenzyme latency, inhibition, and catabolism. The active site can be inhibited by interaction with the N-terminal domain of the tissue inhibitors of metalloproteinases (TIMPs) (5Maskos K. Bode W. Mol. Biotechnol. 2003; 25: 241-266Crossref PubMed Scopus (101) Google Scholar). In addition, the C-terminal part of TIMP-1 binds to the hemopexin domain of both the pro- and active MMP-9, leading to a high affinity interaction (6O'Connell J.P. Willenbrock F. Docherty A.J. Eaton D. Murphy G. J. Biol. Chem. 1994; 269: 14967-14973Abstract Full Text PDF PubMed Google Scholar). MMP-9 may be internalized and subsequently degraded through the cargo receptor low density lipoprotein receptor related protein-1 (LRP-1 or CD91) (7Hahn-Dantona E. Ruiz J.F. Bornstein P. Strickland D.K. J. Biol. Chem. 2001; 276: 15498-15503Abstract Full Text Full Text PDF PubMed Scopus (181) Google Scholar). Another regulatory system for MMP-9 activity is glycosylation (8Van den Steen P.E. Opdenakker G. Wormald M.R. Dwek R.A. Rudd P.M. Biochim. Biophys. Acta. 2001; 1528: 61-73Crossref PubMed Scopus (90) Google Scholar). Structures of N- and O-linked sugars were determined for natural MMP-9 from human neutrophils (9Rudd P.M. Mattu T.S. Masure S. Bratt T. Van den Steen P.E. Wormald M.R. Küster B. Harvey D.J. Borregaard N. Van Damme J. Dwek R.A. Opdenakker G. Biochemistry. 1999; 38: 13937-13950Crossref PubMed Scopus (90) Google Scholar, 10Mattu T.S. Royle L. Langridge J. Wormald M.R. Van den Steen P.E. Van Damme J. Opdenakker G. Harvey D.J. Dwek R.A. Rudd P.M. Biochemistry. 2000; 39: 15695-15704Crossref PubMed Scopus (77) Google Scholar). Little information is available concerning the structures or functions of glycosylation of other MMPs, except that in MT1-MMP, the O-linked glycans on the linker peptide between the active site and the hemopexin domain are essential for the binding of TIMP-2 (11Wu Y.I. Munshi H.G. Sen R. Snipas S.J. Salvesen G.S. Fridman R. Stack M.S. J. Biol. Chem. 2004; 279: 8278-8289Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar). Besides the catalytic site, different domains of MMPs are important for the hydrolysis of particular substrates. Collagenolysis by is on the hemopexin domain and linker peptide D. PubMed Scopus Google Scholar). by is more than by the fibronectin domain Docherty A.J. Murphy G. J. PubMed Scopus Google Scholar). The hemopexin domain of MMP-2 binds monocyte leading to cleavage G.A. 2000; PubMed Scopus Google Scholar). and other have to the of which the and high efficiency on the cleavage Mol. Biotechnol. 22: PubMed Google Scholar). This is from a of because inhibition of the interaction may be used to the cleavage of particular other of the Because no are available on the and functions of the OG domain and on the function of the hemopexin domain of MMP-9, we at the and functional of domains by the of MMP-9 with or The of human MMP-9, a from G. Goldberg (2Wilhelm S.M. Collier I.E. Marmer B.L. Eisen A.Z. Grant G.A. Goldberg G.I. J. Biol. Chem. 1989; 264: 17213-17221Abstract Full Text PDF PubMed Google Scholar), by with the site and site cleavage with and the inserted the the and the in the The by sequence were with and the to the of the This in between the and with the MMP-9 and a functional The of the of at This to a in the of the were and by to the MMP-9 the of the were in to a high which to a high of were with and the of at in MMP-9 by as S. P. Van Damme J. Opdenakker G. J. PubMed Scopus Google Scholar). of human MMP-9 the hemopexin domain or the OG and hemopexin domains, a inserted in the sequence of MMP-9 in the for or for This by with the The which contain the were used for the and for and for The used to a for in which the catalytic and in the OG domain are The which contain the were used for and for of and and for of The OG domain in a 1989; PubMed Scopus Google Scholar). The sequence for the part of MMP-9 the OG domain by the and with hemopexin domain is The hemopexin domain by with the with OG domain is and the were and the and in a the sequence of MMP-9 the OG domain. This in the in were and by with and and in the The by of and in the as for MMP-9 MMP-9 were with catalytic domain of human the of at in The activity at different by and with a Willenbrock F. Murphy G. PubMed Scopus Google Scholar). of MMP-9 to the pomatia for or and for and of the MMP-9 in 50 and 50 were on the MMP-9 with a of for and for and by at and by of the and of of the MMP-9 were and to were and glycans as B. Dwek R.A. Harvey D.J. PubMed Scopus Google Scholar). by of the MMP-9 were to membrane were with of and were on the of T. PubMed Scopus Google by in of with for at and were by to with acid to and for at acid by to with were of glycans were with S.M. PubMed Scopus Google a by on in were from the with glycans were in a of at in 50 the from 50 were through a to were from with were on a with a and with a and were as Rudd P.M. Dwek R.A. PubMed Scopus Google Scholar, L. Mattu T.S. E. Langridge Murphy N. Harvey D.J. Dwek R.A. Rudd P.M. PubMed Scopus Google Scholar). The system a that the for glycans be to glucose Rudd P.M. Dwek R.A. PubMed Scopus Google Scholar). structures were by to the of a of sugars L. Mattu T.S. E. Langridge Murphy N. Harvey D.J. Dwek R.A. Rudd P.M. PubMed Scopus Google Scholar). by glycans were an with a with a a 50 A) and B), with a of at a of The in with 50 and L. Mattu T.S. E. Langridge Murphy N. Harvey D.J. Dwek R.A. Rudd P.M. PubMed Scopus Google Scholar). the cleavage efficiency of by the different MMP-9 collagen den Steen P.E. P. B. Van Damme J. Opdenakker G. J. PubMed Scopus Google Scholar), collagen den Steen P.E. P. Van Damme J. Opdenakker G. Biochemistry. 2004; PubMed Scopus Google Scholar), inhibitor P.E. K. Van S.J. J. Biol. Chem. Full Text PDF PubMed Google Scholar), mouse E. P. S. Van den Steen P.E. Van Damme J. Opdenakker G. J. PubMed Scopus Google Scholar), mouse granulocyte chemotactic den Steen P.E. S.J. P. Van Damme J. Opdenakker G. J. 2003; PubMed Scopus Google Scholar), den Steen P.E. P. Van Damme J. Opdenakker G. 2000; PubMed Google Scholar), J. Fridman R. P. Biochemistry. 1994; PubMed Scopus Google Scholar), soluble E. P. PubMed Scopus Google Scholar), soluble S.M. 2001; Google Scholar), human J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), human T. W. K. P. E. Murphy G. R. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google or in with different of MMP-9 at for the cleavage by MMP-9, the were with the of catalytic domain of human used for the of MMP-9 of the of by the of and the were by the cleavage it from the at which of the MMP-9 the for and mGCP-2/LIX, the cleavage efficiency determined by as den Steen P.E. S.J. P. Van Damme J. Opdenakker G. J. 2003; PubMed Scopus Google Scholar). The binding to and by on a as type were with a of and in the at in at in TIMP-1 at in binding were with by the and The receptor were and were and at in and and were of the with The response is in response the in response between protein and were determined by a binding and of in a from and of natural MMP-9 from human neutrophils and in and as Borregaard N. PubMed Scopus Google Scholar, P. PubMed Scopus (351) Google Scholar). and the and LRP-1 were to in in in were with or natural MMP-9 in In the inhibition and were for with protein and or or to of of or natural MMP-9 in inhibited by of and the and acid to In the the were and to of in the of the degraded were a with with an were at between and in and at were at at were determined the PubMed Scopus Google and were for the of The of protein from its amino acid and The of structures were the J. B. Biophys. J. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). on a and were the J. Google Scholar). The of MMP-9 and the were on the of the N-terminal domains of MMP-9 Y.S. M.S. D. Biol. PubMed Scopus Google and the hemopexin domain in the of MMP-2 E. G. K. 1999; PubMed Scopus Google Scholar). of the OG domain were to the N- and C-terminal The of OG domain and used to structures of an of T.S. Royle L. Langridge J. Wormald M.R. Van den Steen P.E. Van Damme J. Opdenakker G. Harvey D.J. Dwek R.A. Rudd P.M. Biochemistry. 2000; 39: 15695-15704Crossref PubMed Scopus (77) Google Scholar). The of OG domain for the between the OG domain and the hemopexin domain in a in the between and the C-terminal of the OG domain. of the OG domain were by the N-terminal and C-terminal domains as required to a between the and of the OG domain. In the N-terminal and C-terminal domains were a of and O-linked on the of the were the of M.R. A.J. T. Dwek R.A. Chem. Rev. PubMed Scopus Google and in to the glycans, were on the of A.J. S.M. Dwek R.A. Wormald M.R. 2004; PubMed Scopus Google Scholar), the the and to interactions between the glycans and the protein and of of protein of gelatinase were as of the its affinity for and to in a as the by on and of the of and were used to and of the different of MMP-9 MMP-9 at a than natural MMP-9 from human because of in glycosylation of the OG or the hemopexin domain in a in the OG domain is amino acids the hemopexin domain contains amino This be by the of the OG domain of MMP-9 is the of which are can be by In contrast to the the OG domain, and on and in This that the OG domain is essential and for the in the OG domain, in is essential for The of to the and were by from the protein by and The were with that of a and as of the with in a Rudd P.M. Dwek R.A. PubMed Scopus Google Scholar), structures be structures were by of the glycans All the different in the with a are present in the sequence of MMP-9, in the propeptide and in the active domain and the of the glycans, with and the were by and by and This the of glycans on in the propeptide and in the catalytic domain, is and the and of the sugars of The of the sugars in MMP-9, in is in with with natural human MMP-9 (8Van den Steen P.E. Opdenakker G. Wormald M.R. Dwek R.A. Rudd P.M. Biochim. Biophys. Acta. 2001; 1528: 61-73Crossref PubMed Scopus (90) Google and MMP-9 in L. Fridman R. R. S. Chem. PubMed Scopus Google Scholar). of to the OG OG domain of MMP-9 is as it is in other MMPs. sequence contains a low homology with collagen type V (2Wilhelm S.M. Collier I.E. Marmer B.L. Eisen A.Z. Grant G.A. Goldberg G.I. J. Biol. Chem. 1989; 264: 17213-17221Abstract Full Text PDF PubMed Google Scholar). domain the collagen with at In contrast, it contains of the sequence Because on or a is in of or residues or den Steen P. Rudd P.M. Dwek R.A. Opdenakker G. Rev. Mol. Biol. PubMed Scopus Google Scholar), are for of the MMP-9 sequence by the K. R. S. PubMed Scopus Google Scholar), and with of other MMPs, that the OG domain, and domain in MMP-9, contains for O-linked the binding of and of MMP-9 to for the most O-linked glycans on in pomatia HPA, for or and for binding to to to and to This that the OG domain is are most on the other domains of were by a glycosylation of and the different The glycans were from the MMP-9 by with and by and of the and were by of the with of a of to in a L. Mattu T.S. E. Langridge Murphy N. Harvey D.J. Dwek R.A. Rudd P.M. PubMed Scopus Google Scholar), and the a is with a of and a of is a with a of and a of is with a of and a of is in of the and is to have from it in a a are in the the OG domain and the of O-linked and of on the OG domain, the OG domain were and of the MMP-9 the OG structures of the part and the hemopexin domain of MMP-9 have been determined is the three-dimensional of the OG domain. the O-linked sugars influence the three-dimensional of domain. Furthermore, the of a in domain may additional to the three-dimensional structure. It to in a with in the of the hemopexin domain, because are the in MMP-9 for which the is were in with different of of the OG domain which of the different is most of the different MMP-9 were determined by and with the in of the different The the of and are with the of a between and This to be In addition, of (in or of the hemopexin domain to a that the is essential for a of the OG of the of different of the MMP-9 with the different three-dimensional are in for which the with the are in natural MMP-9 from human of the OG The different three-dimensional are in for which the with the are in natural MMP-9 from human of the OG domain in a new of the of of MMP-9 are important for the cleavage of a number of by MMPs Mol. Biotechnol. 22: PubMed Google Scholar). Therefore, it is that the hemopexin and OG domains of MMP-9 contain the cleavage of particular substrates. the different were with the catalytic domain of The for the different the of a number of by the different were were cleavage by MMP-9 for the original of the cleavage and for in of of collagen from the cleavage of collagen with neutrophil for the original of the cleavage and for in of of collagen from the cleavage of collagen with neutrophil in a new Another that the OG domain a between the hemopexin domain and the catalytic site, the cleavage of e.g. to the hemopexin domain. Therefore, the cleavage of with the different cleavage with the which cleaves G.A. 2000; PubMed Scopus Google Scholar). the OG and of MMP-9 for with activity of MMP-9 is regulated in including inhibition by TIMP-1 MMP-9, because it with its the active site, with its C-terminal domain to the hemopexin domain of MMP-9 (6O'Connell J.P. Willenbrock F. Docherty A.J. Eaton D. Murphy G. J. Biol. Chem. 1994; 269: 14967-14973Abstract Full Text PDF PubMed Google Scholar). The of the OG domain in has been Therefore, the binding of the different to TIMP-1 by surface plasmon and and no binding to the binding affinity of for TIMP-1 This the that the OG domain of MMP-9 is important for binding of that in the hemopexin domain is to the N-terminal domains leading to of TIMP-1 of MMP-9 to binding than in the used MMP-9 no The binding than in the used MMP-9 no binding in a new LRP-1 MMP-9 through for MMP-9 is its from extracellular by binding to by internalization and (7Hahn-Dantona E. Ruiz J.F. Bornstein P. Strickland D.K. J. Biol. Chem. 2001; 276: 15498-15503Abstract Full Text Full Text PDF PubMed Scopus (181) Google Scholar). LRP-1 were to and both natural and This be inhibited by the protein and by the of LRP-1 which of MMP-9 are for the binding to the different of MMP-9 were for binding to LRP-1 with the of surface plasmon and LRP-1 with high of the hemopexin domain (in and in the of This that the binding site for LRP-1 in the hemopexin domain of of MMP-9 to The binding of MMP-9 to LRP-1 by surface plasmon The different are in the and natural neutrophil MMP-9, which is to NGAL, MMP-9, which is to and the different of MMP-9 were used to in and The were from the binding and are in of MMP-9 to binding than in the used MMP-9 no The binding than in the used MMP-9 no binding in a new The OG LRP-1 to the binding of MMP-9 to of the OG domain in in a affinity for LRP-1 This that the OG domain is important for the of the hemopexin domain. the binding for and TIMP-1 are to because from which is to TIMP-1 K. Masure S. P. F. J. Van Damme J. Opdenakker G. PubMed Scopus Google Scholar), binds with affinity to LRP-1 as MMP-9 and of as a for is a receptor from the receptor to it to neutrophil gelatinase B-associated Borregaard N. PubMed Scopus Google Scholar). Because as a with MMP-9 in it to neutrophil MMP-9, and human MMP-9, which contain Therefore, which were with MMP-9, and the internalization of the internalization of both and natural MMP-9 and by The internalization be inhibited with and with the essential of megalin. MMP-9 MMP-9 binds to and to which of MMP-9 are for the of the different of MMP-9 for were with the of surface plasmon and neutrophil MMP-9, with NGAL, MMP-9, and to with on the binding and internalization of MMP-9 as a new functional receptor for of hemopexin and OG interactions as for the binding of TIMP-1 and that the of the OG domain the of MMP-9 binding to and of MMP-9 to binding than in the used MMP-9 no The binding than in the used MMP-9 no binding in a new MMP-9 by neutrophils is a of the glycans on natural MMP-9 are and the are sugars (9Rudd P.M. Mattu T.S. Masure S. Bratt T. Van den Steen P.E. Wormald M.R. Küster B. Harvey D.J. Borregaard N. Van Damme J. Dwek R.A. Opdenakker G. Biochemistry. 1999; 38: 13937-13950Crossref PubMed Scopus (90) Google Scholar). In the that the of N- and O-linked glycans are in natural and MMP-9, the of the between N- and O-linked sugars and the of sugars that more than O-linked sugars may be and glycosylation a of domain were and that the O-linked are to the unique OG domain for which no function to This with the sequence of O-linked for which a is in of or or den Steen P. Rudd P.M. Dwek R.A. Opdenakker G. Rev. Mol. Biol. PubMed Scopus Google Scholar), as the OG domain is of of the sequence In natural MMP-9 from human the O-linked sugars consist of the or which are to glycans, of to residues T.S. Royle L. Langridge J. Wormald M.R. Van den Steen P.E. Van Damme J. Opdenakker G. Harvey D.J. Dwek R.A. Rudd P.M. Biochemistry. 2000; 39: 15695-15704Crossref PubMed Scopus (77) Google Scholar). may have functions and may e.g. the protein den Steen P. Rudd P.M. Dwek R.A. Opdenakker G. Rev. Mol. Biol. PubMed Scopus Google Scholar). The O-linked glycans in the of MMP-9 structures with or and Because to functional with natural MMP-9 from human neutrophils with the from the to functions of the between the and for a of the of the protein part of the OG domain with the Because information available on the three-dimensional of the OG domain, a of in and of used to information on the three-dimensional of the OG domain. This that the of the OG domain is unique and as in more and is with the that in the OG domain may a with in the hemopexin domain. This to be of the OG hemopexin domains influence the cleavage of a number of of MMP-9, the that domains contain for substrates. In contrast, both domains a key in the of It has been for that TIMP-1 binds to the C-terminal part of (6O'Connell J.P. Willenbrock F. Docherty A.J. Eaton D. Murphy G. J. Biol. Chem. 1994; 269: 14967-14973Abstract Full Text PDF PubMed Google Scholar, G. R.A. Docherty A.J. Biochemistry. PubMed Scopus Google Scholar). The OG domain is to influence the binding of TIMP-1 to the hemopexin domain, as of the OG domain in affinity for of MMP-9 by internalization and catabolism binding to LRP-1 (7Hahn-Dantona E. Ruiz J.F. Bornstein P. Strickland D.K. J. Biol. Chem. 2001; 276: 15498-15503Abstract Full Text Full Text PDF PubMed Scopus (181) Google Scholar). surface plasmon the hemopexin domain is to be essential for The OG domain is important for its leads to a in The between and the in the binding to TIMP-1 and LRP-1 in the which is This is to be by of because its catalytic activity is to that of It may that the binding for TIMP-1 and LRP-1 in the hemopexin domain are that the OG domain is required for the of the hemopexin domain. TIMP-1 and LRP-1 for binding to MMP-9, the binds to LRP-1 with the affinity as In addition, internalization for the that megalin/LRP-2 is a functional endocytosis receptor for and of MMP-9 by by and endocytosis of MMP-9 is in by LRP-1 by is to be on the expression levels of both It is to that for the endocytosis of MMP-9 in as the and is Rev. 2001; PubMed Scopus Google Scholar). LRP-1 is more in the and on J. G. 269: PubMed Scopus Google Scholar). of surface plasmon it that MMP-9 binds to and that the hemopexin domain of MMP-9 is essential for the OG domain important to high affinity to that the hemopexin domain by the OG domain be a for inhibition by TIMP-1 and internalization of MMP-9 by LRP-1 and megalin. may as in the of the bioavailability of active domains in MMPs have a homology with which is present in The function of hemopexin is to that may be in as and the receptor for the identified as LRP-1 P. PubMed Scopus (351) Google Scholar). The present show that the hemopexin domain of MMP-9 binds Because binding is the function by both hemopexin and the hemopexin domains, it may be that binding to LRP-1 the function of the hemopexin domain in MMPs In MMP-2 and which contain an OG domain, the binding of the hemopexin domain to LRP-1 and other The binding of gelatinase to LRP-1 is by with or or with TIMP-2 Strickland D.K. Bornstein P. J. Biol. Chem. 2001; 276: Full Text Full Text PDF PubMed Scopus Google Scholar, H. G. L. P. E. K. L. H. W. J. Biol. Chem. 2004; 279: Full Text Full Text PDF PubMed Scopus (90) Google Scholar). In the of an unknown receptor binds to the surface and subsequently the to LRP-1 for internalization and J. Biol. Chem. 1999; 274: Full Text Full Text PDF PubMed Scopus Google Scholar). a no or have been for MMP-9 to the hemopexin domain function of MMP-9 may have been by natural a domain with a through the OG domain. Another function for the hemopexin domain demonstrated and of the of gelatinase to the membrane by binding to a the protein S. J. S. B. J. 2004; PubMed Scopus Google Scholar). a of of MMP-9 that the hemopexin domain is essential for the interaction between MMP-9 and LRP-1 and megalin. In addition, it is for the that is a new functional endocytosis receptor for Furthermore, a function of the unique OG domain of MMP-9 is This domain with O-linked glycans and a is important for an binding of the hemopexin domain to the inhibitor TIMP-1 and the internalization cargo LRP-1 and the bioavailability of active S. for of the domain
43
Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension
Robert M. Horton, Henry D. Hunt, Steffan N. Ho et al. · Gene · 1989 · 3.1K citations
S M Wilhelm, Ivan E. Collier, Barry L. Marmer et al. · Journal of Biological Chemistry · 1989 · 1.1K citations · Full text